Strongbridge Biopharma plc Stock News

DUBLIN, Ireland and TREVOSE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme

Strongbridge Biopharma plc's (SBBP) CEO John Johnson on Q4 2020 Results - Earnings Call Transcript

Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 15.38% and 1.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stoc

~ Submitted New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing's Syndrome to U.S. Food & Drug Administration ~

~ RECORLEV® (levoketoconazole) New Drug Application is Supported by Previously-Reported Positive and Statistically Significant Results from the Phase 3 SONICS and LOGICS Studies ~

DUBLIN, Ireland and TREVOSE, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme

The stock price of Strongbridge Biopharma plc (NASDAQ: SBBP) is trading at over 50% pre-market. This is why it happened.

Strongbridge Biopharma is looking at a major inflection year in 2021. In early January, the company provided strong preliminary fourth-quarter guidance but the major catalyst this year is the potentia

DUBLIN, Ireland and TREVOSE, Pa., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and comme

~ Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019

The shares of small-cap biopharma concern are finally seeing some momentum as they rally off oversold levels. The company posted better-than-expected Q3 results in late October and have some potential

Strongbridge Biopharma plc (SBBP) CEO John Johnson on Q3 2020 Results - Earnings Call Transcript

~ Company on Track to Submit New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in the First Quarter of 2021 Following the Reporting of Positive Top-line Data from the LOGICS Stu